|
|
|
|
Clinical studies
Atiprimod successfully completed single and multiple
dose Phase I clinical trials in patients with rheumatoid arthritis (RA).
In the initial Phase I study, 28 patients were given single escalating doses
of drug (0.002 - 1.0 mg/kg), with a 4-month follow-up. Atiprimod was well
tolerated, displaying no clinically relevant changes in any laboratory parameters.
In particular, liver function tests remained in the normal range. The second
Phase I study involved a 28-day multiple-dose-rising study in 35 RA patients.
The study evaluated effect of food on bioavailability, as well as the safety
and pharmocokinetics of repeat dosing. Dosages included 0.1, 1 .0, 5.0,
and 10 mg/day plus a 14-day cohort at 30 mg/day, with 4-month follow-up.
All doses were well tolerated and clinical tests were unremarkable. Individuals
from the 2 Phase I safety studies were also involved in a long-term, open-label
extension trial utilizing 5-mg daily doses of drug. Forty-three patients
entered the study and remained on drug as long as 12 months. Clinical laboratory
results for all patients were unremarkable; in particular liver enzyme levels
remained with the normal range in all patients throughout the study
period. Significantly, reductions in tender and swollen joint counts were
noted in a number of subjects during the course of the first 28-day dosing
period. A Phase II multiple-center trial plan to further evaluate Atiprimod
in RA patients was accepted by the FDA. The trial was never implemented.
|
|
|
technology Links
|
|